MedTrace Logo

Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis

NCT06534814 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-08-02

No results posted yet for this study

Summary

The clinical trial titled "Development and Application of an Artificial Intelligence-Driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis" aims to enhance the detection and treatment of gastric cancer through the utilization of cutting-edge artificial intelligence (AI) technology. This study will develop an AI-driven model designed to accurately identify lymph node metastasis in patients with gastric cancer, which is crucial for staging the disease and planning effective treatment strategies.

The trial will involve a multidisciplinary team of oncologists, radiologists, data scientists, and AI experts who will collaborate to create a robust and precise identification system. Participants will undergo standard diagnostic procedures, and the AI model will analyze imaging and pathological data to predict lymph node involvement.

By comparing the AI model's predictions with traditional diagnostic methods, the study seeks to validate the model's accuracy and efficiency. This approach is expected to improve early detection rates, reduce diagnostic errors, and ultimately lead to better clinical outcomes for patients with gastric cancer. The successful implementation of this AI-driven model could revolutionize the current standards of care and serve as a blueprint for integrating AI technologies in other cancer diagnoses and treatments.

Conditions

  • The Primary Focus of This Study is on Gastric Cancer

Interventions

DIAGNOSTIC_TEST

AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)

The AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM) intervention involves the development and application of an advanced artificial intelligence (AI) system specifically designed to enhance the identification and characterization of lymph node metastasis in patients diagnosed with gastric cancer.

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-12-31
Completion
2030-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06534814 on ClinicalTrials.gov